Affiliation:
1. CREA‐Research Centre for Food and Nutrition Rome Italy
2. Department of Clinical Pharmacy University of Medicine and Pharmacy of Craiova Craiova Romania
3. Department of Biomedical Sciences, College of Medicine Korea University Seoul Republic of Korea
4. Centro de Estudios Tecnológicos y Universitarios del Golfo Veracruz Mexico
5. Department of Clinical Oncology Queen Elizabeth Hospital Kowloon Hong Kong
Abstract
AbstractRaspberries (RBs) (Rubus idaeus) are rich in bioactive compounds with promising anticancer properties. This review provides a comprehensive analysis of the anticancer effects of RBs, highlighting their potential as natural agents in cancer prevention and therapy. Bioactive compounds in RBs induce apoptosis, arrest the cell cycle, inhibit angiogenesis, and suppress metastasis. Preclinical studies demonstrate significant anticancer effects against colon, breast, lung, prostate, and cervical cancers, with clinical studies also supporting their therapeutic potential. Although preclinical findings are encouraging, further large‐scale clinical trials are needed to confirm their efficacy and safety in humans. Optimizing formulations to enhance bioavailability and therapeutic effectiveness is crucial. This review emphasizes the potential of dietary interventions involving RBs as a complementary approach to conventional cancer therapies, paving the way for future research and clinical innovations.